Results 21 to 30 of about 4,527 (165)

Graves’ ophthalmopathy – thyroid eye disease

Journal of Education, Health and Sport, 2019
Graves’ disease (GD) is an autoimmune disorder that affects thyroid. It is caused by antibody, named thyroid-stimulating immunoglobulin (TIS) that acts like thyroid stimulating hormone (TSH), resulting in thyroid hormone overproduction – condition called
Dagna Siedlecka, Wojciech Micał, Ewa Krzewicka-Romaniuk, Rashed Mustafa Nazzal   +3 more
doaj   +3 more sources

Hypoxia increases adipogenesis and affects adipocytokine production in orbital fibroblasts–a possible explanation of the link between smoking and Graves’ ophthalmopathy

International Journal of Ophthalmology, 2014
AIM: To assess the effects of hypoxia on human orbital fibroblasts (OF) on adipogenesis and adipocytokine production.METHODS:Human OF were derived from tissues obtained from patients with Graves’ ophthalmopathy (GO) and from patients without known ...
Chiaw Ling Chng, Oi Fah Lai, Charmaine Sze-Min Chew, Yu Pei Peh, Stephanie Man-Chung Fook-Chong, Lay Leng Seah, Daphne Hsu-Chin Khoo   +6 more
doaj   +1 more source

Extraocular muscle repositioning as the last therapeutic option for a patient with a severe course of Graves’ Ophthalmopathy: a case report

BMC Ophthalmology, 2018
Background Graves’ disease is a common autoimmune inflammatory condition of the thyroid. About one in four of affected patients also develop orbital symptoms like exophthalmos, proptosis and diplopia - called Graves’ Ophthalmopathy.
Andrea Rau, Matthias Klopfer, Niklas Rommel, Mechthild Rau-Fornefeld, Andreas Kolk   +4 more
doaj   +1 more source

Novel observational study protocol to develop a prediction model that identifies patients with Graves’ ophthalmopathy insensitive to intravenous glucocorticoids pulse therapy

BMJ Open, 2021
Introduction Intravenous glucocorticoids pulse therapy is the first-line treatment for moderate-to-severe and active Graves’ ophthalmopathy, with a large proportion of patients having poor efficacy and exposed to the risk of glucocorticoids adverse ...
Jing Sun, Lunhao Li, Yinwei Li, Xuefei Song, Huifang Zhou   +4 more
doaj   +1 more source

World thyroidology news

Клиническая и экспериментальная тиреоидология, 2014
The article is to overview papers: Effect of vitamin C on the absorption of levothyroxine in patients with hypothyroidism and gastritis. Management of neonates born to women with Graves’ disease: a cohort study.
Yuliya Aleksandrovna Manuylova, Anna Evgenyevna Shvedova   +1 more
doaj   +1 more source

Rare concurrent ocular myasthenia gravis and Graves’ ophthalmopathy in a man with Poland syndrome: a case report

BMC Neurology, 2020
Background Ocular myasthenia gravis and Graves’ ophthalmopathy are autoimmune diseases that are mediated by membrane receptors and share many identical clinical processes.
Jingqun Tang, Chao Qin
doaj   +1 more source

The Diagnostic Value of Mean Apparent Propagator‐MRI in Dysthyroid Optic Neuropathy: A Quantitative Analysis of the Entire Visual Pathway

CNS Neuroscience &Therapeutics, Volume 32, Issue 2, February 2026.
The diagnostic model combining orbital and intracranial MAP‐MRI parameters could significantly optimize diagnostic efficiency of dysthyroid optic neuropathy. Comprehensive MAP‐MRI parameters analysis of the entire visual pathway enables a deeper understanding of disease involvement, provides novel insights into the early accurate diagnosis and ...
Mengsha Zou, Dide Wu, Yanglei Cheng, Haodong Qin, Zhiyun Yang, Shubin Hong, Hongzhang Zhu, Cui Yan   +7 more
wiley   +1 more source

Clinical and Radiological Findings in Patients with Newly Diagnosed Graves’ Ophthalmopathy

International Journal of Endocrinology, 2021
Background. Graves’ ophthalmopathy is the most common extrathyroidal manifestation of Graves’ disease. The objective of this study was to investigate the clinical ophthalmological and MRI findings in newly diagnosed Graves’ ophthalmopathy. Methods.
Yakup Cevik, Hande Taylan Sekeroglu, Burce Ozgen, Kadriye Erkan Turan, Ali Sefik Sanac   +4 more
doaj   +1 more source

Research progress on the pathogenesis of Graves’ ophthalmopathy: Based on immunity, noncoding RNA and exosomes

Frontiers in Immunology, 2022
Graves’ ophthalmopathy (GO), also known as thyroid-associated ophthalmopathy, is a common potentially vision-threatening organ-specific autoimmune disease and the most common extrathyroidal manifestation of Graves’ disease.
Jingyi Zheng, Jingyi Zheng, Honghong Duan, Sufang You, Sufang You, Bo Liang, Yuping Chen, Yuping Chen, Huibin Huang   +8 more
doaj   +1 more source

Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization

Laryngoscope Investigative Otolaryngology, Volume 11, Issue 1, February 2026.
Teprotumumab has been proven effective in thyroid eye disease and associated exophthalmos management. Since its FDA approval in 2020, teprotumumab therapy has been a popular choice for managing exophthalmos which has resulted in decreased utilization of orbital decompression surgery, from 36.8% between 2015 and 2020 to 11.1% TED patients between 2020 ...
Nitish Kumar, Pedro Lança Gomes, Gaurav Jategaonkar, Michael J. Marino, Amar Miglani, Devyani Lal   +5 more
wiley   +1 more source